Drugs / semagacestat
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00765115 | Jul 2006 → Sep 2007 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00244322 | Oct 2005 → Dec 2006 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT01035138 | Dec 2009 → Apr 2011 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00762411 | Sep 2008 → Apr 2011 | Alzheimer disease | Eli Lilly and Company | Completed | Missed primary |
| Phase 3 | NCT00594568 | Mar 2008 → May 2011 | Alzheimer disease | Eli Lilly and Company | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2014-07-15 | Eli Lilly and Company | Results New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease lilly.com ↗
Analysis findings demonstrate that cognitive deficits predict subsequent functional deficits and suggest that cognitive decline experienced by patients is followed by an observable related decline in function, consistent with previously proposed hypotheses. |
| 2011-07-19 | Eli Lilly and Company | Results Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research lilly.com ↗
Data were presented today from the first of two Phase III trials of semagacestat, including data from a 32 week follow-up period after dosing was halted in August 2010. |
| 2010-08-17 | Eli Lilly and Company | Results Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials lilly.com ↗
However, by these same measures, patients treated with semagacestat worsened to a statistically significantly greater degree than those treated with placebo. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-07-15 | Eli Lilly and Company | New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease lilly.com ↗ |
| 2011-07-19 | Eli Lilly and Company | Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research lilly.com ↗ |
| 2010-08-17 | Eli Lilly and Company | Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials lilly.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | semagacestat | “INTRODUCTION: LY450139 (semagacestat) inhibits gamma-secretase, a key enzyme for generation of amyloid beta (Abeta), the peptide deposited in plaques in Alzheimer disease (AD).” PMID 20350302 ↗ Mar 20102“Fifteen human healthy volunteers, divided into three groups, received a single dose of placebo or either 140 mg or 280 mg of the γ-secretase inhibitor semagacestat (LY450139).” PMID 26948580 ↗ Mar 2016 |
| Known as | LY450139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00762411 ↗ |
| Action | Inhibit | “inhibits gamma-secretase” PMID 20350302 ↗ Mar 2010 |
| Modality | Small molecule | — CHEMBL520733 ↗ |
| Route | Oral | “Administered orally once daily.” NCT00762411 ↗ |